Fulvestrant in clinical practice: Effectiveness analysis in Uruguayan patients with HR+/HER2- breast cancer
Authors:
- Natalia CamejoNCNatalia Camejo
- Dahiana AmarilloDADahiana Amarillo
- Cecilia CastilloCCCecilia Castillo
- Sofía Badía AlzaSASofía Badía Alza
- Camila BaliñoCBCamila Baliño
- Miguel BanchieriMBMiguel Banchieri
- Juan FagundezJFJuan Fagundez
- Santiago GhigaSGSantiago Ghiga
- Marcos LorierMLMarcos Lorier
- Isabel AlonsoIAIsabel Alonso
- Gabriel David Krygier WaltierGWGabriel David Krygier Waltier
- 24 September 2024
- journal article
- research article
- Published by Medwave Estudios Limitada in Medwave
- Vol. 24 (08) , e2923
Abstract
Introduction Fulvestrant demonstrated benefits in overall survival and progression-free survival in patients with advanced breast cancer, who are hormone receptor-positive and human epidermal growth factor receptor 2 negative. The characteristics, evolution, and survival of patients with hormone receptor-positive, HER2-negative breast cancer treated with fulvestrant were evaluated according to the national treatment coverage protocols of the National Resources Fund, with the aim of understanding the efficacy of fulvestrant in patients treated in usual clinical practice and comparing our results with those from pivotal studies. Methods A database from the National Resources Fund covering the period from 2009 to 2022 was used. Survival curves were assessed using the Kaplan-Meier method, and differences were analyzed using the Log-Rank test. Results A total of 1085 patients with an average age of 63,66 years were included. Following a follow-up of 14 months, the median overall survival was 16 months, and the median progression-free survival was 6 months. The presence of liver and bone metastases was associated with a shorter overall survival. Patients from the public sector and those with a better performance status experienced longer overall survival. Conclusions Our findings provide a valuable perspective for treatment management in a context of limited resources. Overall survival and progression-free survival were somewhat lower than those reported in pivotal clinical trials. The presence of liver and bone metastases was associated with worse prognosis and survival; additionally, patients with worse performance status had shorter overall survival. These findings underscore the need for personalized therapies, opening new lines of future research.Keywords
This publication has 16 references indexed in Scilit:
- Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrantBreast Cancer Research, 2023
- Update on Enrollment of Older Adults Onto National Cancer Institute National Clinical Trials Network TrialsJNCI Monographs, 2022
- Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countriesBMC Health Services Research, 2022
- Cancer statistics, 2022CA: A Cancer Journal for Clinicians, 2022
- Breast cancer liver metastasis: current and future treatment approachesClinical & Experimental Metastasis, 2021
- Untapped Potential of Observational Research to Inform Clinical Decision Making: American Society of Clinical Oncology Research StatementJournal of Clinical Oncology, 2017
- A Review of Fulvestrant in Breast CancerOncology and Therapy, 2017
- Meta-analyses of Adverse Effects Data Derived from Randomised Controlled Trials as Compared to Observational Studies: Methodological OverviewPLOS Medicine, 2011
- Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast CancerJournal of Clinical Oncology, 2010
- Fulvestrant, Formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing After Prior Endocrine TreatmentJournal of Clinical Oncology, 2002